1
|
Zhang C, Zhu B, Feng Y, Cheng Z, Cai X, Feng L, Li J, Lu X. Assessing early tubular protective effects of SGLT2 inhibitor empagliflozin against type 2 diabetes mellitus using functional magnetic resonance imaging. Acta Diabetol 2024; 61:473-483. [PMID: 38117325 DOI: 10.1007/s00592-023-02220-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Accepted: 11/23/2023] [Indexed: 12/21/2023]
Abstract
AIMS To observe the alterations in functional magnetic resonance imaging parameters in normoalbuminuric type 2 diabetic patients undergoing SGLT2 inhibitor empagliflozin treatment and investigate the early tubular protective effects of the inhibitor. METHODS This study was performed in normoalbuminuric type 2 diabetes mellitus patients (UACR < 30 mg/g, eGFR ≥ 60 ml/min/1.73 m2). The patients were divided into the intervention group (empagliflozin) and the control group (27 cases each). The intervention group was treated with 10 mg/day empagliflozin tablets orally, while the control group had adjustments to their basic treatment stage. The patients were treated for 6 weeks. RESULTS The baseline clinical data of the two groups were comparable (P˃0.05). The intervention group exhibited better improvements in blood lipid profiles and more significant reductions in blood uric acid levels compared to the control group (P < 0.05). The two groups had No significant difference in blood pressure changes (P˃0.05). Notably, the intervention group demonstrated a greater reduction in UACR and a more substantial decline in eGFR than the control group (P < 0.05). Regarding functional magnetic resonance imaging parameters, the MD value of the renal medulla region in the intervention group increased after treatment, while the MR2* value of the renal medulla region decreased (P < 0.05). CONCLUSIONS SGLT2 inhibitor empagliflozin can reduce UACR and eGFR levels in early type 2 diabetic patients with normal proteinuria. Moreover, empagliflozin therapy led to an increase in the MD value and a decrease in the MR2* value of the renal medulla, evidencing the early tubular protective effects of this therapy.
Collapse
Affiliation(s)
- Chuangbiao Zhang
- Department of Endocrinology, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China
| | - Beibei Zhu
- Endoscopy Center, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China
| | - Youzhen Feng
- Medical Imaging Center, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China
| | - Zhongyuan Cheng
- Medical Imaging Center, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China
| | - Xiangran Cai
- Medical Imaging Center, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China
| | - Lie Feng
- Department of Endocrinology, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China
| | - Jiaying Li
- Department of Endocrinology, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China.
| | - Xiaohua Lu
- Department of Endocrinology, First Affiliated Hospital of Jinan University, No.613, Huangpu Avenue West, Guangzhou, 510630, Guangdong Province, China
| |
Collapse
|